Extended-Release Oral Ketamine Effective for Treatment-Resistant Depression
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 17, 2024 -- For patients with treatment-resistant depression, racemic ketamine, given as an extended-release tablet (R-107), administered orally, is effective, safe, and well tolerated, according to a study published online June 24 in Nature Medicine.
Paul Glue, M.D., from the University of Otago in Dunedin, New Zealand, and colleagues examined the safety and tolerability of racemic ketamine given orally compared with other routes of administration in a phase 2 multicenter clinical trial. A total of 231 male and female patients with treatment-resistant depression and Montgomery-Asberg Depression Rating Scale (MADRS) scores ≥20 received R-107 tablets (120 mg) for five days and were assessed on day 8. One hundred sixty-eight responders on day 8 were randomly assigned to receive double-blind R-107 doses of 30, 60, 120, or 180 mg or placebo, twice weekly for a further 12 weeks in a 1:1:1:1:1 ratio.
The researchers found that the primary objective was met; at 13 weeks, the least-squares mean difference of the MADRS score for the 180-mg tablet group and placebo was −6.1 (95 percent confidence interval 1.0 to 11.16; P = 0.019). During double-blind treatment, relapse rates showed a dose response, from 70.6 percent for placebo to 42.9 percent for the 180-mg dose. There was excellent tolerability noted, with no blood pressure changes, minimal reports of sedation, and minimal dissociation. Headache, dizziness, and anxiety were the most common adverse events.
"Use of an extended-release oral dosage ketamine formulation may be advantageous compared with intranasal or intravenous dosing, in terms of reduced intensity of dissociation, lower risk of abuse, reduced frequency and intensity of sedative and cardiovascular side effects, and improved convenience for administration in the community," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Douglas Pharmaceuticals, which is developing extended-release racemic ketamine and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
Suicidal Ideation, Behaviors Not Increased With GLP-1 RAs for Seniors With T2D
TUESDAY, July 16, 2024 -- For older adults with type 2 diabetes (T2D), use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is not associated with a significantly...
Psychological Risks Increased for Transgender Youth at Gender Identity Milestones
MONDAY, July 15, 2024 -- Transgender youth have an increased risk for attempting suicide or running away from home in association with gender identity milestones, with the...
Globally, Loneliness Affects More Than One-Fifth of People
THURSDAY, July 11, 2024 -- Loneliness strikes more than one in five people worldwide, with 23 percent saying they felt lonely "a lot of the previous day," according to the results...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.